GlassScriptPhysician profile
Charbal Butrous Bazo
NPI 1689643496
$8,046.56
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $1,341 · 2021: $2,284 · 2022: $1,601 · 2023: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,200 · Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,200.00 |
| Food and Beverage | $449.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,644.07 | 2021-2023 | Qulipta, Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $732.77 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $691.97 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $624.31 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $565.78 | 2019-2023 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $304.59 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $302.23 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $243.40 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.76 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $215.96 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.06 | 2019-2021 | |
| Orexo US, INC. | $212.54 | 2019-2022 | |
| Pfizer INC. | $173.24 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $170.20 | 2022 | |
| Amgen INC. | $170.07 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $164.17 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $158.03 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $140.96 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $130.35 | 2021 | |
| Sanofi-Aventis U.S. LLC | $112.80 | 2021-2022 | |
| Eisai INC. | $112.36 | 2019-2021 | |
| Alkermes, INC. | $106.51 | 2021-2023 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $91.53 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $81.64 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $61.38 | 2022 | |
| Almatica Pharma LLC | $60.55 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.65 | 2019-2022 | |
| Amarin Pharma, INC. | $49.46 | 2019-2020 | |
| Mylan Specialty L.P. | $49.27 | 2021-2023 | Yupelri |
| Indivior INC. | $39.11 | 2019-2022 | |
| Biogen, INC. | $30.06 | 2021 | |
| Lilly USA, LLC | $27.56 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $19.65 | 2022 | |
| Fortovia Therapeutics, INC. | $16.14 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.08 | 2022 | |
| Circassia INC. | $13.34 | 2019 | |
| Uswm, LLC | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charbal Bazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.